Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma

Pi Lin Sung, Yi Hua Jan, Shih Chieh Lin, Chao Cheng Huang, Hao Lin, Kuo Chang Wen, Kuan Chong Chao, Chiung Ru Lai, Peng Hui Wang, Chi Mu Chuang, Hua Hsi Wu, Nae Fang Twu, Ming Shyen Yen, Michael Hsiao, Chi Ying F. Huang

Research output: Contribution to journalArticlepeer-review

72 Citations (Scopus)

Abstract

The interplay between tumor microenvironment and cancer that causes chemoresistance remains unclear. By analyzing public available microarray datasets, we identified that periostin (POSTN) was overexpressed in cancer stroma in epithelial ovarian cancer (EOC) patients. Immunohistochemistry analysis showed overexpression of stromal POSTN is a powerful independent poor prognostic predictor for EOC patients. Furthermore, patients with high levels of stromal POSTN tend to have higher percentage of cisplatin resistance compared to those with low levels of stromal POSTN. Moreover, we found POSTN treatment can induce cisplatin resistant and activate AKT pathway in A2780 cells in vitro. Inhibition of AKT activity by AKT inhibitor MK-2206 abolished POSTN-induced AKT activation and cisplatin resistance in vitro. Taken together, we found high POSTN expression in cancer microenvironment is correlated with poor prognosis in EOC patients and associated with platinum resistance. The effect of POSTN in cancer stroma cells may activate AKT pathway in tumor and AKT inhibitor can be beneficial to augment the efficacy of existing cancer therapeutics.

Original languageEnglish
Pages (from-to)4036-4047
Number of pages12
JournalOncotarget
Volume7
Issue number4
DOIs
Publication statusPublished - 2016
Externally publishedYes

Keywords

  • Biomarker
  • Epithelial ovarian cancer
  • Microenvironment
  • Periostin
  • Platinum resistance

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma'. Together they form a unique fingerprint.

Cite this